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ABSTRACT 
Advanced glycation end products (AGEs) are involved in the aging and the development of common 
chronic diseases. Hydroxytyrosol (HT) and its acetate derivative (HTA) exert a significant inhibitory 
activity on the formation of fluorescent AGEs in bovine serum albumin glycation model systems induced 
by methylglyoxal (IC50 value of 0.48 and 0.58 μmol/mL, respectively) and glucose (IC50 2.30 and 2.92 
μmol/mL, respectively). Furthermore, HT and HTA showed a relevant carbonyl scavenging capacity 
toward methylglyoxal and glyoxal, which are the most potent promoters of the glycation in vivo, at 
molar reaction rates from 0.2 to 10 (carbonyl:phenol). However, carbonyl trapping capacity was 
significantly more effective against methylglyoxal (IC50 0.19 μmol/mL) than glyoxal (IC50 0.26 μmol/mL). 
At equimolar concentrations, the ester linkage did not significantly affect the antiglycative activity and 
carbonyl trapping capacity of the orthodiphenolic ring structure. Results were confirmed with the 
specific inhibition of the formation of the principal AGEs. Formation of carboxymethyl-lysine, 
argpyrimidine and carboxyethyl-lysine was significantly reduced by 61.9, 71.4 and 20.9 %, respectively. 
HT and its esters could be considered for upscaling studies as promising natural strategy against adverse 
consequences of protein glycation. 
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INTRODUCTION 
Glycation occurs physiologically in the course of aging with the formation of advanced glycation end 
products (AGEs) when a free amino group of protein interacts with the carbonyl group of glucose [1]. In 
addition, dicarbonyl compounds, such as methylglyoxal (MGO) and glyoxal (GO), are also formed from 
the sugar degradation being key intermediates in AGEs formation [2]. Human plasma levels for GO and 
MGO have been estimated to be in the 0.3–1.5 μmol/L range, and their concentrations are increased in 
diabetes and chronic renal failure [3, 4]. AGEs are a group of complex and heterogeneous products with 
different fluorescent and non-fluorescent structures, such as Nɛ-carboxymethyl-lysine (CML), Nɛ-
carboxyethyl-lysine (CEL), pentosidine, argpyrimidine (ArgP), glyoxal lysine dimers, or methylglyoxal 
lysine dimmers among others [1, 5, 6]. AGEs that accumulate in tissue altering irreversibly the 
functionality and protein structure by binding to certain amino acids such as lysine and arginine are 
structurally modified [2]. Therefore, AGEs might damage the tissues and organs underlying inflammation 
through specific receptor, and its accumulation is accelerated in diabetes, neurodegenerative and 
autoimmune diseases. AGEs have been associated with the process of normal aging and the 
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development of common chronic diseases such as Alzheimer’s disease, atherosclerosis or diabetes and 
its numerous long-term complications [1, 7]. 
 
The high incidence of these chronic diseases and the importance to maintain a healthy aging have caused 
that research focuses on the search for AGE inhibitors [8]. Initially, aminoguanidine (AG) was studied as 
synthetic AGE inhibitors, but due to toxic side effects it was discharged. Later, compounds from a 
natural source such as pyridoxamine, quercetin, curcumin, creatine or carnitine were considered as the 
most appropriate alternative [6, 9, 10]. Nowadays, certain bioactive phytochemicals are particularly 
relevant as natural AGE inhibitors since phenolic compounds have redox activity which could contribute 
to the inhibition of glycation process [11]. This hypothesis is supported by clinical studies where the 
development of type II diabetes might be ameliorated by natural antioxidants [12]. However, the specific 
biological consequences of the dietary AGEs are still under debate [13]. 
 
Hydroxytyrosol (HT, 2-(3,4-dihydroxyphenyl) ethanol) is an orthodiphenolic compound present in our 
diet, and in pharmacological preparations, as a secoiridoide derivative in free form or as an acetate 
ester. HT is essential component of oleuropein, present in olive oil and mill waste in appreciable 
quantities [14]. Dietary intake of olive oil polyphenols has been estimated to be around 9 mg (within 25–
50 olive oil/day), where at least 1 mg of them is derived from free HT and 8 mg related to their elenolic 
esters and oleuropein [15]. Chemical structure of HT and its derivative, hydroxytyrosol acetate (HTA) 
(3,4-dihydroxyphenylethyl acetate), are shown in Fig. 1. Studies of HT in vivo and in vitro have shown 
various biological activities with potential beneficial health effects. For instance, it has been associated 
with anti-inflammatory, hypocholesterolemic, neuroprotective, antibacterial, cardioprotective, anticancer 
and insulin-stimulatory activities [14, 16]. Previous studies have linked former effects with the 
antioxidant activity of orthodiphenolic compounds. In vitro and in vivo studies proved that HT is a 
potent scavenger of free radicals and could exert an indirect protection by modulating the endogenous 
antioxidant defense system [15]. Although most of the studies refer to HT, it was found that HTA 
presents rather similar antioxidant activity than HT [17]. Restraint of oxidative stress by HT and 
prevention of glucose autooxidation also allowed performing a protection against certain metabolic 
diseases such as diabetes and its complications [17–19]. However, no alternative mechanisms for the 
antiglycative activity of HT have been elucidated apart of its antioxidant and antiradical properties. 
Recently, a number of in vitro studies have pointed out the direct relationship between the major 
constituents in olive leaf [20], or olive oil wastewater [21] and the inhibition of fluorescent AGEs and 
the mitigation of the carbonyl stress by trapping reactive dicarbonyls [22]. However, those studies just 
focused on the inhibition of the formation of fluorescent derived AGEs, but there is no information of 
the specific inhibition on the formation of AGEs structures as formed in vivo. 
 
This study aimed to investigate the antiglycative activity of HT and its acetate derivative directly on the 
formation of fluorescent AGEs by applying different in vitro models, but also through the inhibition of 
major AGEs, such as CML, CEL and ArgP. Additionally, ability of HT and HTA against a direct trapping 
of MGO and GO, and the inhibition of the formation of fructosamine adducts were also evaluated. 
 
MATERIALS AND METHODS 
Chemical and materials 
d(+)-Glucose (GLC), bovine serum albumin (BSA), MGO (40 % aqueous solution), GO (40 % aqueous 
solution), aminoguanidine (AG), 5-methylquinoxaline (5-MQ), nitrotetrazolium blue chloride (NBT), o-
phenyldiamine (OPD), Nα-acetyl-l-lysine, o-phthaldialdehyde (OPA), sodium borohydride, 
perfluoropentanoic acid (purity >97 %), heptafluorobutyric acid (HFBA) and standards of phenolic acids 
were provided by Sigma (St. Louis, MO, USA). HT and HTA (purity >99 %) were acquired from Seprox 
Biotech (Madrid, Spain). Pyridoxamine (PM) was acquired from Fluka Chemical (Madrid, Spain). Sodium 
dihydrogen phosphate monohydrate, sodium carbonate anhydrous, glacial acetic acid and high-
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performance liquid chromatography (HPLC)-grade methanol were purchased from Merck (Darmstadt, 
Germany). Nε-carboxymethyl-l-lysine (CML, ≥97 %), Nε-carboxyethyl-l-lysine (CEL, ≥97 %), CMLd2, 
CEL-d4 and argpyrimidine (ArgP) were obtained from PolyPeptide Laboratories (Strasbourg, France). 
The Milli-Q water was obtained by an Elix3 water purification system coupled to a Milli-Q Advance 10 
module (Millipore, Molsheim, France). All other chemicals were of analytical grade and supplied by 
Panreac Química (Barcelona, Spain). 
 
In vitro glycation assay with bovine serum albumin induced by methylglyoxal and glucose 
Two glycation models on BSA, one induced by MGO (BSA–MGO assay), and the other induced by 
glucose (BSA–GLC assay), were carried out as described by Mesias et al. [23]. The BSA solution (0.525 
μmol/mL) was prepared in phosphate buffer (0.01 mol/L, pH 7.4), containing 0.1 g/mL sodium azide and 
penicillin G (0.05 g/ mL) to ensure aseptic conditions and EDTA (0.026 g/mL) to prevent metal-catalyzed 
oxidation. The MGO stock solution (5.551 μmol/mL) and glucose stock solution (975.381 μmol/mL) 
were prepared in phosphate buffer (0.1 mol/L, pH 7.4). In the BSA–MGO assay, 200 μL of BSA solution 
was incubated with 400 μL of MGO solution (5.551 μmol/mL) at 37 °C for 14 days in the presence of 
100 μL of the target compound. In the BSA–GLC assay, 200 μL of BSA solution was incubated with 400 
Μl of GLC solution at 37 °C for 21 days in the presence of 100 μL of the target compound. HT, HTA 
and phenolic acids were dissolved in methanol/water (60/40, v/v), and concentrations from 0.058 to 5.8 
μmol/mL were prepared. In both assays, a blank without target compounds and a positive control with 
AG (7.694 μmol/mL) were incubated at the same conditions. A portion of each system at the initial time 
was kept at −80 °C until measurement. In parallel, standards (from 0.058 to 5.8 μmol/mL) were 
dissolved in phosphate buffer (0.1 mol/L, pH 7.4) and incubated at 37 °C for 14 days (BSA–MGO assay) 
or 21 days (BSA– GLC) in order to measure their intrinsic fluorescence. 
 
The fluorescence intensity is as an index of the formation of fluorescent AGEs. A Synergy™ MX 
multimode microplate spectrophotometer (BioTek Instruments, Winooski, VT, USA) was used. The 
formation of AGEs was characterized by fluorescence with excitation and emission at 340 and 420 nm 
for the BSA–MGO assay and 360 and 420 nm for the BSA–GLC. The intrinsic fluorescence of the 
standards incubated under the same conditions was subtracted to the global fluorescence in each BSA–
MGO or BSA–GLC system. The percentage inhibition of AGEs formation was calculated according to 
the following equation: The concentration required to inhibit the glycation by 50 % (IC50) was 
calculated from the dose–response curve using the Microsoft Excel computer software. 
 
Fructosamine adduct assay 
Procedure was carried out as described by Baker et al. [24] with slight modifications. The extent of 
glycation on BSA was determined by measuring the reducing activity of NBT for Amadori compound in 
alkaline solution. Under these conditions, fructosamine has the ability to reduce NBT to tetrazinolyl 
radical (NBT+) forming a colored compound called monoformazan. The samples from the BSA–GLC 
assay were used for the determination. Thereby, 50 μL of sample was mixed with 450 μL of NBT and 
the mixture was incubated in darkness at 37 °C for 60 min. Then, in each well of the microplate were 
added 100 μL of mixture and 100 μL of sodium carbonate buffer (0.1 mol/L, pH 10.35) except wells of 
blank that only contented 200 μL of sodium carbonate buffer (0.1 mol/L, pH 10.35). The presence of 
fructosamine was characterized by the absorbance of monoformazan at 530 nm using a BioTek 
microplate spectrophotometer. The inhibition of the fructosamine formation, expressed as percentage, 
was calculated taking into consideration the absorbance in the presence/absence of the inhibitor. 
 
Determination of reactive lysine in BSA using OPA 
The reactive lysine residues in BSA were determined as described by Goodno et al. [25]. BSA solution 
(200 μL, 35 mg/mL in phosphate buffer 0.01 mol/L, pH 7.4) was incubated at 37 °C for 1, 2 and 3 days in 
the absence or the presence of HT (100 μL, 4.112 μmol/mL in 60:40 methanol/ water). The samples (20 
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μL) were mixed with 200 μL of protein buffer (50 % buffer borate (0.1 M, pH 10), 10 % SDS (20 %, 
w/w) and 40 % water). Nα-acetyl-lysine in formic acid 0.1 %, at various concentrations was used for 
calibration (1000–50 μM). The presence of reactive lysine was measured by fluorescence of at 360/460 
nm (excitation/ emission wavelength) and expressed as percentage of amino acid blockage. 
 
Evaluation of direct MGO and GO trapping capacity 
Direct MGO and GO trapping capacity was determined as described by Mesias et al. [23] with 
modifications. The MGO solution (5.551 μmol/mL) or GO solution (5.686 μmol/mL) was dissolved in 
phosphate buffer (0.1 mol/L, pH 7.4), 5-MQ (internal standard, 1 mg/mL) in 100 μL of MGO or GO 
solution. The mixture was incubated at 37 °C up to 168 h. After that, 200 μL of OPD solution was 
added, rapidly vortexed for 5 s and was kept in darkness for 30 min where the derivatization reaction of 
unreacted dicarbonyl to corresponding quinoxaline derivative was complete. The quantification of Q, 2-
MQ and 5-MQ was carried out on Shimadzu HPLC system equipped with an LC-20AD pump, an SIL-
10ADvp autosampler, a CTO-10ASVP oven and an SPD-M20A diode array detector. Chromatographic 
separation was performed on a Mediterranean- Sea-ODS2 column (150 mm × 3 mm, 5 μm; 
Teknokroma, Barcelona, Spain). The injection volume was 10 μL, and the flow rate was 0.5 mL/min. The 
total run time was 7 min in isocratic conditions (mobile phase of 5 mL/L acetic acid/methanol, 50:50 v/v). 
The chromatograms were recorded at 315 nm being the retention times of Q, 2-MQ and 5-MQ, 3.4, 4.1 
and 5.6 min, respectively. The amount of unreacted MGO was calculated from the ratio of 2-MQ and 5-
MQ as compared with control at the initial time. The amount of unreacted GO was calculated from the 
ratio of Q and 5-MQ as compared with control at the initial time. The percentage of inhibition of MGO 
or GO was calculated with the next formula. The concentration required to inhibit the glycation by 50 
% (IC50) was obtained from the dose–response curves using Microsoft Excel computer software 
 
Determination of CML and CEL by LC‑MS/MS 
The formation of CML and CEL was determined as described by Niquet-Léridon and Tessier [26] with 
minor modifications. Sample (1 mL, containing 10 mg of protein) was incubated with 1.5 mL of sodium 
borate (0.2 M, pH 9.2) and 1 mL of sodium borohydride (1 M in 0.1 M NaOH) for 4 h at room 
temperature. Then, samples were hydrolyzed with 5 mL of HCl (final concentration of 6 M) for 20 h at 
110 °C, filtered and 500 μL was dried in a Speed-Vac concentrator (ThermoFisher Scientific, 
Courtaboeuf, France). Finally, residue was reconstituted in 1 mL of NFPA 5 mM (containing 0.1 mL of 
CML-d2 or CEL-d4 at 1 μg/mL). LC-MS/MS was performed with an Agilent 1200 HPLC system (Agilent 
Technologies, Palo Alto, CA, USA) coupled to a triple quadrupole Agilent (G6410B) via electrospray 
ionization operating in positive mode. Sample (10 μL) was injected on Hypercarb column (100 mm × 2.1 
μm, 5 μm, ThermoFisher Scientific). The flow rate was 0.5 mL/min, and the isocratic elution was applied 
using a mobile phase of 5 mM NFPA / acetonitrile (95:5 v/v). The product ion at m/z 84 was used for 
quantification of CML (m/z 205), CML-d2 (m/z 207), CEL (m/z 219) and CEL-d4 (m/z 223). The ratio of 
response factor of CML or CEL to that their respective labeled internal standards was used for 
calculation of CML or CEL in samples. Data were processed using Masshunter Data Acquisition and 
MassHunter Qualitative Analysis (Agilent Technologies). Results were expressed as μmol CML or CEL 
/g protein. 
 
Determination of argpyrimidine by LC‑fluorescence 
Sample preparation was the same as described above for lysine-derived AGEs until obtaining the freeze-
dried protein hydrolysate as described by Wilker et al. [27]. The analysis of ArgP (10 μL sample 
injection) was carried out on a Prominence HPLC system with an RF-20A XS fluorescence detector 
(Shimadzu Corporation, Kyoto, Japan). Sample was eluted onto a Mediterranean-Sea-ODS2 column (250 
mm × 4 mm, 5 μm; Teknokroma, Barcelona, Spain) at a flow rate of 0.8 mL/min under gradient elution. 
The solvent system gradient was of HFBA (1 mL/L) as solvent A and ACN (500 mL/L) containing HFBA 
(1 mL/L) as solvent B. The following multistep linear gradient was applied: 0 min, 20 % B; 25 min, 100 % 
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B; 26 min, 100 % B; and 27–37 min, 20 % B. ArgP was detected at 335 and 385 nm for excitation and 
emission wavelength, respectively, and eluted at 15.1 min. Calibration was carried out in the range 
0.001–0.01 mg/mL with pure standard. Results were expressed as μmol ArgP/g protein. 
 
Statistical analysis 
Data were analyzed using the Statgraphics Centurion XV Statistical program (Herndon, VA, USA). 
Homogeneity of variances was evaluated by the test of Levene. Analysis of variance was performed using 
ANOVA procedures followed by a Bonferroni test or Tamhane test when the variances were 
homogeneous or non-homogeneous, respectively. Differences were considered significant at p < 0.05. 
Data from three independent assays were expressed as the mean value ± SD. 
 
RESULTS AND DISCUSSION 
The antiglycative activity of HT and HTA was evaluated by measuring the inhibition of the formation of 
fluorescent AGEs in a model of glycation with BSA under physiological conditions. Accumulation of 
AGE-specific fluorescence is a general measure of overall protein glycation damage, and it is a widely 
used tool for glycation research in in vitro and in vivo studies [6]. Since HT and HTA were dissolved in a 
methanolic solution (60 % v/v), the lack of potential interferences in the glycation models was evaluated. 
Different proportions of methanol:water up to 100 % after 14 or 21 days of incubation at 37 °C for 
BSA–MGO and BSA–GLC systems, respectively, were tested. In addition, the intrinsic fluorescence of 
HT and HTA was residual, accounting for <5 % of the total fluorescence in the glycation models. 
 
The antiglycative capacity of HT and its acetate derivative in a range from 0.405 to 8.282 μmol/mL were 
assayed in the BSA–GLC (21 days/37 °C) and BSA–MGO (14 days/37 °C) systems. Glycation reaction in 
the BSA–GLC system proceeds slower than the BSA–MGO system since autoxidation of glucose to 
form dicarbonyl compounds is minimized in the presence of EDTA. Another limiting step in the BSA–
GLC system is the conversion of glucose to its open-chain form to condensate with the amino residues 
[2]. Figure 2 shows the percentage of inhibition of the formation of fluorescent AGEs related to the 
molar ratio between the glycative stressor and the orthodiphenolic compound. Both HT and HTA 
exerted a dosedependent antiglycative activity in BSA–MGO and BSA–GLC systems. Maximum 
inhibition (98.6 %) was reached at 4.112 μmol/mL in the BSA–MGO system (Fig. 2a), corresponding to a 
molar ratio (MGO:phenolic compound) of 0.8. At lower molar ratio, the activity was kept without 
significant differences (p < 0.05) among samples. The potency of the antiglycative capacity of HTA was 
similar to that HT at equimolar concentration of MGO, although response of HTA was significantly 
lower than HT at 0.405 μmol/mL (8 molar ratio MGO:phenolic compound). AG was used as positive 
control since it inhibits AGEs formation by reacting with carbonyl groups of reducing sugars, Amadori 
products and dicarbonyl intermediates [6]. AG reached 99.6 % of inhibition at the same molar ratio 
MGO:AG. IC50 values of 0.48 and 0.58 μmol/mL were calculated for HT and HTA in the BSA–MGO 
system, respectively. In the BSA–GLC system (Fig. 2b), although a similar trend was observed, the 
antiglycative activity of HT was significantly higher than HTA at higher molar ratio with GLC. 
Additionally, IC50 value of 2.30 and 2.92 μmol/mL was calculated for HT and HTA, respectively, for 
their antiglycative activity in the BSA–GLC system. 
 
The extent of the sugar-induced modifications was further evaluated in the BSA–GLC system by the 
formation of the Amadori products using the fructosamine assay. In this assay, glucosone is the primary 
carbohydrate oxidation product formed from the Amadori compounds. In this sense, fructosamine assay 
is an efficient tool to identify at which level of the glycation cascade is acting our target compounds. 
Table 1 shows the inhibition of the formation of the Amadori products in the presence of different 
concentrations of HT and HTA (0.405–8.282 μmol/mL). Both HT and HTA are able to prevent the 
formation of the Amadori product but in an efficiently manner. Results are correlated with the 
antiglycative effect of HT and HTA in the BSA–GLC assay. HT was significantly more effective than HTA 
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in the prevention of the formation of Amadori products at a molar ratio (GLC:phenolic compound) of 
600, whereas there were no differences at lower molar ratio since a complete inhibition was already 
reached. These results on fructosamine could explain the higher activity of HT than HTA exerted in the 
inhibition of the fluorescent AGEs in the BSA–GLC assay. 
 
The protection of reactive lysine residues in the protein by HT was investigated. HT was able to protect 
the modification of the 24.3, 39.7 and 45.1 % of amino group in just 1, 2 and 3 days of incubation, 
respectively. Recently, Navarro and Morales [22] shown that the reactivity of orthodiphenolic 
compounds against MGO and GO was effective enough to compete with free lysine, arginine and 
histidine and subsequently to prevent the formation of carbonylderived AGEs. However, the mechanism 
of reaction was not concluded. Our results pointed out that ortodiphenolic compounds not only could 
mitigate the extension of the glycation process by reducing the formation of the Amadori products but 
also by protecting the lysine residues to initiate the glycation reaction. 
 
In the BSA–MGO system, our results showed the protective effect of HT on the formation of the 
fluorescent AGEs at similar molar ratio with MGO. The evaluation of the specific scavenging capacity of 
inhibitors toward dicarbonyl compounds gives a complementary view of the potential antiglycative 
activity of target compounds, and it can be used as an effective strategy to prevent protein modifications 
and AGEs formation [8, 28, 29]. The role of dicarbonyl compounds was further investigated in MGO 
and GO trapping model systems (Fig. 3) at different molar ratios (dicarbonyl:phenolic compound). Both 
HT and HTA displayed similar dicarbonyl trapping activity against GO regardless the molar ratio (Fig. 
3b). However, significant differences between HT and HTA were found at molar ratio higher than 1 for 
trapping MGO (Fig. 3a). Dicarbonyls and particularly MGO and GO are key promoter in the glycation 
process [30], and they are important precursors in the formation of AGEs [1, 11]. Dicarbonyls are 
formed from oxidative reaction to sugars, Schiff bases, Amadori products and lipid oxidation. Then, 
dicarbonyls irreversibly and progressively modify proteins overtime and yield AGEs which are 
contributing to the complications associated with aging. These modifications involve lysine residues, but 
arginine is predominantly modified with the formation of fluorescent compounds [5]. Our results on 
direct dicarbonyl trapping are in line with the results obtained for the inhibition of fluorescent AGEs in 
the BSA–MGO assay shown in Fig. 2a. 
 
Additionally, the trapping capacity, expressed as IC50, of different structure-related phenolic compounds 
(gallic acid, caffeic acid, protocatechuic acid, chlorogenic acid, sinapinic acid, ferulic acid, gentisic acid and 
p-coumaric acid) is given in Table 2. Results confirm the promising dicarbonyl trapping ability of HT, and 
HTA as compared with other phenolic acids. It has been described that the hydroxyl groups in the 
phenyl ring have electron-donating properties and enhance the reactivity of MGO by just nucleophilic 
addition. Navarro and Morales [22] identified two major adducts during the incubation of HT with MGO 
at physiological conditions. In order to gain more insight into the dicarbonyl trapping abilities of HT and 
HTA, the kinetic of the trapping over time was investigated. Figure 4 shows the time course of the 
disappearance of dicarbonyl compounds (expressed as MGO or GO trapping capacity) in the reaction 
mixtures (100 mM PBS, 37 °C) at the same dicarbonyl:phenolic compound molar ratio. PM was used as 
a positive control of the reaction, and HT and HTA behave as PM did (data not shown). The kinetic of 
HT and HTA was similar, time dependent and progressively is reaching a maximum activity at 168 h of 
incubation (94.6 and 95.1 %, respectively). Again, it was observed that HT and HTA were quantitatively 
less effective for trapping GO as compared with MGO at any time of incubation. 
 
The antiglycative properties of HT were further investigated on the specific inhibition of the formation 
of the most representative AGEs (Fig. 1). CML is the most abundant non-fluorescent AGEs and together 
with CEL has been used as markers of the extension of the glycation in foods and physiological systems 
[1, 2, 30]. In our BSA–GLC glycation system that contains EDTA, CML is basically formed by the 
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condensation of glucose with the ε-amino group of lysine, where the Amadori rearrangement product 
fructosyllysine is unstable intermediate and undergoes oxidation to form CML. Then a BSA–GO model 
was carried out to enhance specifically the formation of CML. In contrast, the system BSA–MGO was 
used for the determination of CEL and ArgP. ArgP is the major fluorescent AGEs result of the reaction 
between two molecules of MGO and arginine [5], and CEL is a lysine-MGO-derived AGE [3]. In this 
investigation was not included pentosidine since it was not defined a model system with ribose. In the 
investigation with CML, CEL and ArgP, the incubation time of the glycation models was settled at 7 days 
for BSA–MGO and BSA–GO systems since the maximum concentration of these AGEs was already 
reached at that time. BSA–GO system was prepared in similar way to BSA–MGO. 
 
The CML formation in the BSA–GO system (7 days of incubation at 37 °C) is shown in Fig. 5a. AG was 
used as a positive control at the same molar ratio than HT. The formation of CML was significantly 
reduced in the presence of HT at all the concentration assayed, being significantly stronger than AG at 
the highest molar ratio with GO. CEL is formed in low amounts in the BSA–MGO system, and AG is 
able to inhibit its formation very effectively in a dose–response manner. In regard to the formation of 
CEL (Fig. 5b), it was clearly observed a dose-dependent effective mitigation by AG, even at the highest 
MGO:AG molar ratio. However, HT was not efficient enough to impair the formation of CEL where 
only a 20.9 % of inhibition is reached at equimolar concentration. As described by Navarro and Morales 
[22], arginine is the preference site of reaction for MGO, followed by histidine, and lysine is less prone 
to react with MGO that it could explain the low rate of formation of CEL. As expected, the arginine-
MGO derived AGE ArgP was largely formed in the BSA–MGO (Fig. 5c) and ArgP formation is largely 
dependent on the presence of AG and HT. For both compounds, the formation of ArgP was significantly 
reduced to 47.4 and 49.2 % for AG and HT, respectively, as compared with the control at the highest 
MGO molar ratio. It is noteworthy to mention that the formation of ArgP at equimolar concentration 
was completely impaired by AG and significantly reduced at 71.4 % by HT. Two molecules of MGO are 
necessary for the formation of ArgP, and the presence of free MGO is the limiting factor in the reaction. 
 
The protein glycation process can be divided into the early stage in which the Amadori products are 
formed, and the advanced stage in which Amadori products undergo a number of rearrangements to 
form AGEs. Our results on the fructosamine assay and blockage of reactive amino residues reveal that 
HT and HTA have also an inhibitory effect on the formation of the Amadori product at the early stage 
of the glycation. But, HT and HTA are also effective inhibitors of the advanced stage since the formation 
of fluorescent AGEs, CML and ArgP were effectively suppressed. Results are promising to upscale the in 
vitro experiments to in vivo systems since HT is abundant in olive oil and efficiently absorbed [15, 16]. 
In this regard, Miro-Casas et al. [18] investigated the bioavailability of HT in animals and humans 
administrated with virgin olive oil have demonstrated that HT absorption, plasmatic levels and urine 
excretion have a direct response to the intake. The maximum concentration of HT in plasma is reached 
at 32 min with a half-life of 2.43 h. Nearly 98 % of the HT appears in plasma as conjugated HT and its 
metabolites suggesting extensive intestinal/hepatic metabolism of the dietary HT [15]. Serra et al. [31] in 
an intervention experiment feeding rats with olive extract shown that HT was absorbed and rapidly 
distributed (56.8 nmol/L plasma after 1 h) practically to all organs through the blood stream more 
effectively than the luteolin derivatives (0.68 nmol/L plasma after 1 h). Other study in rats supports that 
after an intravenously injection of HT, it was quickly absorbed and distributed, being preferential kidney 
uptake. The distribution of its different metabolites depends on the enzymatic conversion, being sulfo-
conjugated forms, the metabolites from a sequential oxidation (3,4-dihydroxyphenylacetaldehyde, 3,4-
dihydroxy-phenylacetic acid, 4-hydroxy-3-methoxy-phenylacetic acid) and the methylated derivative 
form (4-hydroxy-3-methoxy-phenylethanol) the majority in kidney, brain, heart, liver and brain, 
respectively [32]. 
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In conclusion, HT and its acetate derivate, HTA, were evaluated with the aim of investigating their 
antiglycative capacity using different in vitro models. These orthodiphenolic compounds exhibited a 
potent inhibitory activity on the formation of CML, and ArgP formation and very likely the carbonyl 
trapping capacity plays a major role. Results are in line with Navarro and Morales [22] who described 
the mechanism of action for trapping carbonyl species by HT due to electrophilic aromatic substitution 
of the orthodiphenyl ring. Additionally, the reactivity of amino residues and fructosamine formation was 
efficiently inhibited so it could be assumed that HT and HTA are also acting at the early stages of 
glycation process. This study has shown by first time that HT and its acetate ester act at multiple steps 
of the glycation process and the reactive part of the molecular structure is the orthodiphenyl ring 
without major relevance to the ester linkage. These in vitro results are promising and pointed out that it 
is realistic to define further steps in vivo before to propose HT as a natural AGEs inhibitor. 
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FIGURES AND TABLES 
 
Figure 1. Structure of hydroxytyrosol (a), hydroxytyrosol acetate (b), ε-N-carboxymethyl-L-lysine (c), 
ε-N-carboxyethyl-L-lysine (d), argypyrimidine (e). 
 
Figure 2. Antiglycative activity of hydroxytyrosol (solid bar) and hydroxytyrosol acetate (empty bar) on 
the formation of fluorescent AGEs in the BSA-MGO assay (a), and in the BSA-GLC assay (b). Results are 
expressed as mean (percentage of inhibition respect to control) ± standard deviation for n=4. Different 
letters denote significant differences (P < 0.05). 
 
Figure 3. Methylglyoxal (a) and glyoxal (b) trapping capacity of hydroxytyrosol (solid bar) and 
hydroxytyrosol acetate (empty bar) at different molar ratio. Results are expressed as mean ± standard 
deviation for n=4. Different letters denote significant differences (P < 0.05). 
 
Figure 4. Methylglyoxal (a) and glyoxal (b) trapping capacity of hydroxytyrosol (solid circle) and 
hydroxytyrosol acetate (open circle) incubated (37C for 168 h) at the equimolar conditions (0.581 
µmol/mL). Different letters denote significant differences (P < 0.05). 
 
Figure 5. Effect of hydroxytyrosol (empty bar) on the inhibition of the formation of carboxymethyl-
lysine (a), carboxyethyl-lysine (b), and argypyrimidine (c) at different molar ratio of methylglyoxal and 
glyoxal. Aminoguanidine was used as reference (grey bar). BLK corresponds to control (solid bar). 
Results are expressed as mean ± standard deviation for n=3. Different letters denote significant 
differences (P < 0.05) with control.  
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TABLES 
Table 1. Determination of the inhibition of the formation of Amadori products by the 
fructosamine assay by hydroxytyrosol (HT) and hydroxytyrosol acetate (HTA) in the range from 
0.405 to 8.282 µmol/L. 
 
Molar Ratio Concentration HT HTA 
Glucose:Phenolic µmol/mL Inhibition (%) Inhibition (%) 
1200 0.405 2.9 ± 2.3a 7.2 ± 2.0a 
600 0.811 66.5 ± 7.4b 7.3 ± 2.1a 
120 4.112 100 ± 8.0c 100 ± 2.5c 
60 8.282 100 ± 6.7c 100 ± 7.7c 
 
       a Results are expressed as mean ± SD for n=4.  
  Different letters in same column denote significant differences P<0.05). 
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Table 2. Methylglyoxal trapping capacity of hydroxytyrosol, hydroxytyrosol acetate, gallic acid, 
caffeic acid, protocatechuic acid, chlorogenic acid (CGA), sinapinic acid, ferulic acid, gentisic acid, 
and p-coumaric acid. Pyridoxamine is used as reference. 
 
Standard IC50 (µmol/mL) 
Hydroxytyrosol 0.195 
Hydroxytyrosol acetate 0.204 
Pyridoxamine 0.059 
Gallic acid 0.176 
Caffeic acid 0.222 
Protocatechuic acid 0.389 
Chlorogenic acid 0.367 
Sinapinic acid 0.892 
Ferulic acid 1.648 
Gentisic acid 3.179 
p-Coumaric acid 2.985 
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